文档介绍：Advances in Clinical Medicine 临床医学进展, 2021, 11(12), 5785-5789
Published Online December 2021 in Hans. , 王丽芳. 阿替利珠单抗致免疫相关性肺炎伴感染 1 例[J]. 临床医学进展, 2021, 11(12): 5785-5789.
DOI: .1112855王梦雅，王丽芳
and so on. Atezolizumab is a monoclonal antibody against human immunoglobulin G1 (IgG4) that
targets programmed death receptor 1 (PD-1). By binding to PD-L1 and CD80 of tumor cells, the ac-
tivity of T lymphocytes can be restored and immune escape can be blocked to exert anti-tumor ef-
fect. Atezolizumab is the first approved ICIs for the first-line therapy in patients with extensive pe-
riod small-cell lung cancer, but immune related adverse events (irAEs) such as immune associated
pneumonia cannot be diagnosed early, resulting in complex clinical symptoms. We report a case of
severe immune-associated pneumonia complicated with acute infection in a patient with exten-
sive period SCLC treated with atezolizumab.
Keywords
Small-Cell Lung Cancer, Atezolizumab, PD-1 Inhibitor, Immune-Associated Pneumonia
Copyright © 2021 by aut